x | QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
o | TRANSITION REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 |
Delaware | 27-2004382 | |
(State or other jurisdiction of incorporation or organization) | (I.R.S. Employer Identification No.) | |
11055 Flintkote Avenue, San Diego, California | 92121 | |
(Address of principal executive offices) | (Zip Code) | |
(858) 952-7570 | ||
(Registrant’s telephone number, including area code) |
Large accelerated filer o | Accelerated filer o | Non-accelerated filer x | Smaller reporting company x | Emerging growth company o |
Page | ||
March 31, 2019 | December 31, 2018 | ||||||
Assets | |||||||
Current assets: | |||||||
Cash and cash equivalents | $ | 11,330,079 | $ | 11,453,133 | |||
Accounts receivable and unbilled receivable | 115,676 | 167,755 | |||||
Prepaid expenses | 890,725 | 1,144,377 | |||||
Total current assets | 12,336,480 | 12,765,265 | |||||
Property and equipment, net | 293,361 | 1,304,433 | |||||
Operating lease right-of-use assets | 1,816,286 | — | |||||
Other assets | 87,073 | 102,798 | |||||
Total Assets | $ | 14,533,200 | $ | 14,172,496 | |||
Liabilities and Stockholders’ Equity | |||||||
Current liabilities: | |||||||
Accounts payable | $ | 466,747 | $ | 664,840 | |||
Accrued expenses | 2,021,737 | 1,813,842 | |||||
Operating lease liabilities | 796,246 | — | |||||
Deferred rent, current portion | — | 486,636 | |||||
Total current liabilities | 3,284,730 | 2,965,318 | |||||
Derivative financial instruments—warrants | 42,076 | 32,315 | |||||
Operating lease liabilities, net of current portion | 1,520,213 | — | |||||
Deferred rent, net of current portion | — | 1,090,671 | |||||
Total Liabilities | 4,847,019 | 4,088,304 | |||||
Commitments and contingencies (Note 8) | |||||||
Stockholders’ equity | |||||||
Preferred stock, $0.001 par value, 20,000,000 shares authorized; 277,100 designated as Series A Convertible Preferred Stock; 60,600 shares outstanding at March 31, 2019 and December 31, 2018 with liquidation preference of $606,000 at March 31, 2019 and December 31, 2018; 200,000 designated as Series C Convertible Preferred Stock; 200,000 and 0 shares outstanding at March 31, 2019 and December 31, 2018, respectively | 260 | 60 | |||||
Common stock, $0.0001 par value, 150,000,000 shares authorized; 4,525,354 and 3,831,880 shares issued and outstanding at March 31, 2019 and December 31, 2018, respectively | 7,906 | 7,742 | |||||
Additional paid-in capital | 207,652,843 | 202,267,605 | |||||
Service receivables | (1,604,513 | ) | — | ||||
Accumulated deficit | (196,370,315 | ) | (192,191,215 | ) | |||
Total stockholders’ equity | 9,686,181 | 10,084,192 | |||||
Total liabilities and stockholders’ equity | $ | 14,533,200 | $ | 14,172,496 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Revenues: | |||||||
Royalties | $ | 62,021 | $ | 49,055 | |||
Services and other | 99,937 | 51,081 | |||||
Total revenues | 161,958 | 100,136 | |||||
Costs and expenses: | |||||||
Cost of revenues | — | 366,344 | |||||
Research and development | 2,648,599 | 1,883,838 | |||||
Selling, general and administrative | 1,475,122 | 2,504,977 | |||||
Total operating expenses | 4,123,721 | 4,755,159 | |||||
Loss from operations | (3,961,763 | ) | (4,655,023 | ) | |||
Interest income | 64,743 | 21,771 | |||||
Interest expense | — | (24,236 | ) | ||||
Loss from change in fair value of derivative financial instruments—warrants | (9,761 | ) | (129,689 | ) | |||
Other income, net | 2,010 | 1,000 | |||||
Net loss | (3,904,771 | ) | (4,786,177 | ) | |||
Preferred stock dividend payable on Series A Convertible Preferred Stock | (6,060 | ) | (6,060 | ) | |||
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance | (268,269 | ) | — | ||||
Net loss attributable to common stockholders | $ | (4,179,100 | ) | $ | (4,792,237 | ) | |
Net loss per common share — basic | $ | (1.02 | ) | $ | (6.23 | ) | |
Net loss per common share — diluted | $ | (1.02 | ) | $ | (6.23 | ) | |
Weighted-average shares outstanding — basic | 4,086,561 | 768,951 | |||||
Weighted-average shares outstanding — diluted | 4,086,561 | 768,951 |
Preferred Stock Shares | Preferred Stock Amount | Common Stock Shares | Common Stock Amount | Additional Paid-In Capital | Service Receivable | Accumulated Deficit | Total Stockholders’ Equity | ||||||||||||||||||||||
Balance, January 1, 2019 | 60,600 | $ | 60 | 3,831,879 | $ | 7,742 | $ | 202,267,605 | $ | — | $ | (192,191,215 | ) | $ | 10,084,192 | ||||||||||||||
Stock-based compensation | — | — | — | — | 200,067 | — | — | 200,067 | |||||||||||||||||||||
Issuance of common stock, preferred stock and warrants for clinical trial funding commitment, net of expenses and discount of $40,000 and $235,640, respectively | 200,000 | 200 | 183,334 | 110 | 1,634,690 | (1,675,000 | ) | — | (40,000 | ) | |||||||||||||||||||
Deemed dividend recognized on beneficial conversion features of Series C Convertible Preferred Stock issuance | — | — | — | — | 268,269 | — | (268,269 | ) | — | ||||||||||||||||||||
Issuance of common stock upon exercise of warrants | — | — | 497,313 | 50 | 3,282,216 | — | — | 3,282,266 | |||||||||||||||||||||
Issuance of common stock upon vesting of restricted stock units | — | — | 6,362 | 4 | (4 | ) | — | — | — | ||||||||||||||||||||
Preferred stock dividend payable on Series A Convertible Preferred Stock | — | — | — | — | — | — | (6,060 | ) | (6,060 | ) | |||||||||||||||||||
Issuance of common stock for share rounding as a result of reverse stock split | — | — | 6,466 | — | — | — | — | — | |||||||||||||||||||||
Release of clinical trial funding commitment | — | — | — | — | — | 70,487 | — | 70,487 | |||||||||||||||||||||
Net loss | — | — | — | — | — | — | (3,904,771 | ) | (3,904,771 | ) | |||||||||||||||||||
Balance, March 31, 2019 | 260,600 | $ | 260 | 4,525,354 | $ | 7,906 | $ | 207,652,843 | $ | (1,604,513 | ) | $ | (196,370,315 | ) | $ | 9,686,181 |
Preferred Stock Shares | Preferred Stock Amount | Common Stock Shares | Common Stock Amount | Additional Paid-In Capital | Accumulated Deficit | Total Stockholders’ Equity | |||||||||||||||||||
Balance, January 1, 2018 | 60,600 | $ | 60 | 733,217 | $ | 5,279 | $ | 179,546,954 | $ | (173,046,186 | ) | $ | 6,506,107 | ||||||||||||
Stock-based compensation | — | — | — | — | 1,406,131 | — | 1,406,131 | ||||||||||||||||||
Issuance of common stock upon exercise of warrants | — | — | 71,347 | 514 | 1,448,653 | — | 1,449,167 | ||||||||||||||||||
Issuance of common stock upon vesting of restricted stock units | — | — | 12,567 | 90 | (90 | ) | — | — | |||||||||||||||||
Preferred stock dividend payable on Series A Convertible Preferred Stock | — | — | — | — | — | (6,060 | ) | (6,060 | ) | ||||||||||||||||
Cumulative adjustment upon adoption of ASC 606 | — | — | — | — | — | 109,922 | 109,922 | ||||||||||||||||||
Net loss | — | — | — | — | — | (4,786,177 | ) | (4,786,177 | ) | ||||||||||||||||
Balance, March 31, 2018 | 60,600 | $ | 60 | 817,131 | $ | 5,883 | $ | 182,401,648 | $ | (177,728,501 | ) | $ | 4,679,090 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Operating activities | |||||||
Net loss | $ | (3,904,771 | ) | $ | (4,786,177 | ) | |
Adjustments to reconcile net loss to net cash used in operating activities: | |||||||
Depreciation and amortization | 45,911 | 252,480 | |||||
Stock based compensation expense | 200,067 | 1,406,131 | |||||
Deferred rent | — | (79,586 | ) | ||||
Change in fair value of derivative financial instruments—warrants | 9,761 | 129,689 | |||||
Release of clinical trial funding commitment | 70,487 | — | |||||
Changes in operating assets and liabilities: | |||||||
Decrease in other assets | 15,725 | — | |||||
Decrease in accounts receivable and unbilled receivable | 52,079 | 72,674 | |||||
Decrease in prepaid expenses and other current assets | 179,691 | 97,684 | |||||
Decrease in operating lease right-of-use assets | 154,058 | — | |||||
Increase in accounts payable and accrued expenses | 3,635 | 50,958 | |||||
Decrease in operating lease liabilities | (186,689 | ) | — | ||||
Net cash used in operating activities | (3,360,046 | ) | (2,856,147 | ) | |||
Investing activities: | |||||||
Capital expenditures | (5,274 | ) | (5,100 | ) | |||
Net cash used in investing activities | (5,274 | ) | (5,100 | ) | |||
Financing activities: | |||||||
Costs related to the clinical trial funding commitment | (40,000 | ) | — | ||||
Proceeds from exercise of warrants | 3,282,266 | 1,449,167 | |||||
Repayments of equipment line of credit | — | (156,526 | ) | ||||
Net cash provided by financing activities | 3,242,266 | 1,292,641 | |||||
Net change in cash and cash equivalents | (123,054 | ) | (1,568,606 | ) | |||
Cash and cash equivalents—Beginning of period | 11,453,133 | 8,225,764 | |||||
Cash and cash equivalents—End of period | $ | 11,330,079 | $ | 6,657,158 | |||
Supplementary disclosure of cash flow activity: | |||||||
Cash paid for taxes | $ | 800 | $ | — | |||
Cash paid for interest | $ | — | $ | 16,417 | |||
Supplemental disclosure of non-cash investing and financing activities: | |||||||
Preferred stock dividend payable on Series A Convertible Preferred Stock | $ | 6,060 | $ | 6,060 | |||
Deemed dividend recognized for beneficial conversion features of Series C Convertible Preferred Stock issuance | $ | 268,269 | $ | — | |||
Common stock, Series C Convertible Preferred Stock and warrants issued in connection with clinical trial funding commitment, net of discount of $235,640 | $ | 1,675,000 | $ | — |
• | Seek collaborators for product candidates at an earlier stage than otherwise would be desirable and on terms that are less favorable than might otherwise be available; and |
• | Relinquish licenses or otherwise dispose of rights to technologies, product candidates or products that the Company would otherwise seek to develop or commercialize themselves, on unfavorable terms. |
• | Raising capital through public and private equity offerings; |
• | Introducing operation and business development initiatives to bring in new revenue streams; |
• | Reducing operating costs by identifying internal synergies; and |
• | Engaging in strategic partnerships. |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Numerator: Net loss attributable to common shareholders | $ | (4,179,100 | ) | $ | (4,792,237 | ) | |
Net loss used for diluted loss per share | $ | (4,179,100 | ) | $ | (4,792,237 | ) | |
Denominator for basic and diluted net loss per share: | |||||||
Weighted-average shares used to compute basic loss per share | 4,086,561 | 768,951 | |||||
Weighted-average shares used to compute diluted net loss per share | 4,086,561 | 768,951 | |||||
Net loss per share attributable to common stockholders: | |||||||
Basic | $ | (1.02 | ) | $ | (6.23 | ) | |
Diluted | $ | (1.02 | ) | $ | (6.23 | ) |
March 31, | |||||
2019 | 2018 | ||||
Options to purchase Common Stock | 80,345 | 105,394 | |||
Warrants to purchase Common Stock | 3,302,093 | 255,818 | |||
Restricted Stock Units | 18,620 | 5,134 | |||
Series A Convertible Preferred Stock | 877 | 877 | |||
Series C Convertible Preferred Stock | 333,334 | — | |||
3,735,269 | 367,223 |
Fair Value Measurements at March 31, 2019 | |||||||||||||||
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total | ||||||||||||
Assets: | |||||||||||||||
Money market fund (1) | $ | 11,258,846 | $ | — | $ | — | $ | 11,258,846 | |||||||
Total Assets | $ | 11,258,846 | $ | — | $ | — | $ | 11,258,846 | |||||||
Liabilities: | |||||||||||||||
Derivative financial instruments—warrants | $ | — | $ | — | $ | 42,076 | $ | 42,076 | |||||||
Total Liabilities | $ | — | $ | — | $ | 42,076 | $ | 42,076 |
Fair Value Measurements at December 31, 2018 | |||||||||||||||
Quoted Prices in Active Markets for Identical Assets and Liabilities (Level 1) | Significant Other Observable Inputs (Level 2) | Significant Unobservable Inputs (Level 3) | Total | ||||||||||||
Assets: | |||||||||||||||
Money market fund (1) | $ | 11,392,093 | $ | — | $ | — | $ | 11,392,093 | |||||||
Total Assets | $ | 11,392,093 | $ | — | $ | — | $ | 11,392,093 | |||||||
Liabilities: | |||||||||||||||
Derivative financial instruments—warrants | $ | — | $ | — | $ | 32,315 | $ | 32,315 | |||||||
Total Liabilities | $ | — | $ | — | $ | 32,315 | $ | 32,315 |
Description | Balance at December 31, 2018 | Realized (gains) or losses | Balance at March 31, 2019 | |||||||||
Derivative financial instruments—warrants | $ | 32,315 | $ | 9,761 | $ | 42,076 |
As of March 31, 2019 | As of December 31, 2018 | ||||||
Furniture and office equipment | $ | 775,030 | $ | 775,030 | |||
Leasehold improvements | 102,230 | 1,962,230 | |||||
Laboratory equipment | 682,508 | 677,234 | |||||
1,559,768 | 3,414,494 | ||||||
Less—accumulated depreciation and amortization | (1,266,407 | ) | (2,110,061 | ) | |||
Property and equipment, net | $ | 293,361 | $ | 1,304,433 |
Three Months Ended March 31, 2019 | ||||
Operating lease cost | $ | 194,462 | ||
Operating sublease income | (99,937 | ) | ||
Net operating lease cost | $ | 94,525 |
March 31, 2019 | ||||
Operating lease ROU assets | $ | 1,816,286 | ||
Current operating lease liabilities | $ | 796,246 | ||
Non-current operating lease liabilities | 1,520,213 | |||
Total operating lease liabilities | $ | 2,316,459 | ||
Weighted-average remaining lease term–operating leases | 2.8 years | |||
Weighted-average discount rate–operating leases | 6.5 | % |
Three Months Ended March 31, 2019 | ||||
Cash paid for amounts included in the measurement of lease liabilities: | ||||
Operating cash flows from operating leases | $ | 226,364 | ||
ROU assets obtained in exchange for lease obligations: | ||||
Operating leases | $ | 2,503,148 |
Year Ending December 31, | Operating Leases | Sublease Income | Net Operating Leases | |||||||||
2019 (excluding the three months ended March 31, 2019) | $ | 614,107 | $ | 233,187 | $ | 380,920 | ||||||
2020 | 941,670 | — | 941,670 | |||||||||
2021 | 968,165 | — | 968,165 | |||||||||
2022 | 5,868 | — | 5,868 | |||||||||
2023 | 3,423 | — | 3,423 | |||||||||
Total future minimum lease payments | 2,533,233 | $ | 233,187 | $ | 2,300,046 | |||||||
Less imputed interest | (216,774 | ) | ||||||||||
Total | $ | 2,316,459 |
Operating Leases | Sublease Income | Net Operating Leases | |||||||||
2019 | $ | 914,540 | $ | (333,124 | ) | $ | 581,416 | ||||
2020 | 941,670 | — | 941,670 | ||||||||
2021 | 968,165 | — | 968,165 | ||||||||
2022 | 5,868 | — | 5,868 | ||||||||
2023 | 3,423 | — | 3,423 | ||||||||
Total | $ | 2,833,666 | $ | (333,124 | ) | $ | 2,500,542 |
Three Months Ended March 31, | |||||
2019 | 2018 | ||||
Estimated fair value of Trovagene common stock | 3.15-3.75 | 22.32-25.20 | |||
Expected warrant term | 3.8-4.1 years | 0.8-5.1 years | |||
Risk-free interest rate | 2.22-2.49% | 1.76-2.54% | |||
Expected volatility | 102-105% | 91-116% | |||
Dividend yield | 0 | % | 0 | % |
Date | Description | Number of Warrants | Derivative Instrument Liability | ||||||
December 31, 2018 | Balance of derivative financial instruments—warrants liability | 64,496 | $ | 32,315 | |||||
Change in fair value of derivative financial instruments—warrants during the period recognized as a loss in the condensed statements of operations | — | 9,761 | |||||||
March 31, 2019 | Balance of derivative financial instruments—warrants liability | 64,496 | $ | 42,076 |
Three Months Ended March 31, | |||||||
2019 | 2018 | ||||||
Included in research and development expense | $ | 110,081 | $ | 395,709 | |||
Included in cost of revenue | — | 39,631 | |||||
Included in selling, general and administrative expense | 89,986 | 970,791 | |||||
Total stock-based compensation expense | $ | 200,067 | $ | 1,406,131 |
Three Months Ended March 31, | |||||
2019 | 2018 | ||||
Risk-free interest rate | 2.33 | % | 2.43 | % | |
Dividend yield | 0 | % | 0 | % | |
Expected volatility | 99 | % | 90 | % | |
Expected term | 5.1 years | 5.2 years |
Total Options | Weighted-Average Exercise Price Per Share | Intrinsic Value | ||||||||
Balance outstanding, December 31, 2018 | 83,345 | $ | 146.09 | $ | — | |||||
Granted | 8,384 | $ | 4.26 | |||||||
Canceled / Forfeited | (11,384 | ) | $ | 70.82 | ||||||
Balance outstanding, March 31, 2019 | 80,345 | $ | 142.11 | $ | — | |||||
Exercisable at March 31, 2019 | 68,345 | $ | 160.62 | $ | — |
Number of Shares | Weighted-Average Grant Date Fair Value Per Share | Intrinsic Value | ||||||||
Non-vested RSUs outstanding, December 31, 2018 | 30,132 | $ | 14.36 | $ | 95,005 | |||||
Granted | 167 | $ | 4.04 | |||||||
Vested | (6,362 | ) | $ | 19.96 | $ | 20,323 | ||||
Forfeited | (5,317 | ) | $ | 13.04 | ||||||
Non-vested RSUs outstanding, March 31, 2019 | 18,620 | $ | 12.72 | $ | 69,825 |
Total Warrants | Weighted-Average Exercise Price Per Share | Weighted-Average Remaining Contractual Term | ||||||
Balance outstanding, December 31, 2018 | 3,649,341 | $ | 8.91 | 4.4 | ||||
Granted | 150,065 | $ | 3.76 | |||||
Exercised | (497,313 | ) | $ | 6.60 | ||||
Balance outstanding, March 31, 2019 | 3,302,093 | $ | 9.02 | 4.2 |
• | Complete Phase 1b dose escalation cohorts and identify the recommended Phase 2 dose (“RP2D”) for the Phase 2 continuation trial (dependent upon the number of dose escalation cohorts required to reach the maximum tolerated dose or RP2D of onvansertib). |
• | Provide topline safety and efficacy data on the combination of onvansertib + LDAC and the combination of onvansertib + decitabine in patients treated through the end of 2018. |
• | Present data from the AML trial at key oncology conferences, including the American Society of Hematology (“ASH”) annual meeting. |
• | Initiate the Phase 2 segment of the AML trial, which will enroll approximately 32 patients, for continued evaluation of safety and efficacy of onvansertib in combination with either LDAC or decitabine (provided the RP2D has been determined in Phase 1b). |
• | Presented data from the mCRPC trial at the Genitourinary Cancers Symposium (“ASCO-GU”) in February 2019. |
• | Complete enrollment and evaluation of the 3 safety lead-in patients in the second arm (2-week dosing schedule) with onvansertib at 24 mg/m2 in combination with abiraterone acetate (Zytiga®) and prednisone. |
• | Provide topline preliminary safety and efficacy data of onvansertib in combination with abiraterone acetate (Zytiga®) and prednisone in patients treated. |
• | Present data from the mCRPC trial at key oncology conferences throughout 2019 and first quarter 2020. |
• | Announced Data Demonstrating Significant Synergy of Onvansertib in Combination with Venetoclax in Cell Model of Venetoclax-Resistant AML. |
• | Announced Update to Phase 1b/2 Trial Data Presented at AACR - Additional Patients Achieve Complete Response at Two Highest Dose Levels of Onvansertib. |
• | Announced Early Data from Phase 2 Trial Indicates Activity of Onvansertib in Prostate Cancer Patients Showing Initial Resistance to Anti-Androgen Therapy. |
• | Announced Phase 1b/2 Dose Escalation Trial of Onvansertib in Relapsed/Refractory AML Demonstrates Safety, Tolerability and relative Durability with Complete Responses at Highest Dose Levels. |
• | Announced Presentation Update on Phase 2 Study of Onvansertib in Combination with Zytiga® in Patients with mCRPC at ASCO-GU. |
• | Entered Agreement with PoC Capital, LLC to Fund Clinical Development of Onvansertib in mCRC. |
• | Announced New Patent Issued for Combination of Onvansertib with Anti-Androgen Drugs to Treat Non-Metastatic and Metastatic Prostate Cancer. |
Three Months Ended March 31, | |||||||||||
2019 | 2018 | Increase (Decrease) | |||||||||
Royalties | $ | 62,021 | $ | 49,055 | $ | 12,966 | |||||
Services and other | 99,937 | 51,081 | 48,856 | ||||||||
Total revenues | $ | 161,958 | $ | 100,136 | $ | 61,822 |
Three Months Ended March 31, | |||||||||||
2019 | 2018 | Increase (Decrease) | |||||||||
Salaries and staff costs | $ | 403,888 | $ | 402,068 | $ | 1,820 | |||||
Stock-based compensation | 110,081 | 395,709 | (285,628 | ) | |||||||
Clinical trials, outside services, and lab supplies | 1,927,929 | 849,988 | 1,077,941 | ||||||||
Facilities and other | 206,701 | 236,073 | (29,372 | ) | |||||||
Total research and development | $ | 2,648,599 | $ | 1,883,838 | $ | 764,761 |
Three Months Ended March 31, | |||||||||||
2019 | 2018 | Increase (Decrease) | |||||||||
Salaries and staff costs | $ | 522,797 | $ | 690,170 | $ | (167,373 | ) | ||||
Stock-based compensation | 89,986 | 970,791 | (880,805 | ) | |||||||
Outside services and professional fees | 457,832 | 482,410 | (24,578 | ) | |||||||
Facilities and other | 404,507 | 361,606 | 42,901 | ||||||||
Total selling, general and administrative | $ | 1,475,122 | $ | 2,504,977 | $ | (1,029,855 | ) |
Three Months Ended March 31, | |||||||||||
2019 | 2018 | Increase (Decrease) | |||||||||
Net loss attributable to common shareholders | $ | (4,179,100 | ) | $ | (4,792,237 | ) | $ | (613,137 | ) | ||
Net loss per common share — basic | $ | (1.02 | ) | $ | (6.23 | ) | $ | (5.21 | ) | ||
Net loss per common share — diluted | $ | (1.02 | ) | $ | (6.23 | ) | $ | (5.21 | ) | ||
Weighted average shares outstanding — basic | 4,086,561 | 768,951 | 3,317,610 | ||||||||
Weighted average shares outstanding — diluted | 4,086,561 | 768,951 | 3,317,610 |
Exhibit Number | Description of Exhibit | |
101.INS | XBRL Instance Document | |
101.SCH | XBRL Taxonomy Extension Schema | |
101.CAL | XBRL Taxonomy Extension Calculation Linkbase | |
101.LAB | XBRL Taxonomy Extension Labels Linkbase | |
101.PRE | XBRL Taxonomy Extension Presentation Linkbase | |
101.DEF | XBRL Taxonomy Extension Definition Linkbase |
TROVAGENE, INC. | ||
May 7, 2019 | By: | /s/ Thomas Adams |
Thomas Adams | ||
Chief Executive Officer | ||
TROVAGENE, INC. | ||
May 7, 2019 | By: | /s/ Brigitte Lindsay |
Brigitte Lindsay | ||
VP, Finance |
1. | I have reviewed this quarterly report on Form 10-Q of Trovagene, Inc. (the “Registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions); |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
May 7, 2019 | /s/ Thomas Adams |
Thomas Adams | |
Chief Executive Officer |
1. | I have reviewed this quarterly report on Form 10-Q of Trovagene, Inc. (the “Registrant”); |
2. | Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report; |
3. | Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report; |
4. | The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have: |
a. | Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared; |
b. | Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles; |
c. | Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and |
d. | Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and |
5. | The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions); |
a. | All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and |
b. | Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting. |
May 7, 2019 | /s/ Brigitte Lindsay |
Brigitte Lindsay | |
VP, Finance |
May 7, 2019 | /s/ Thomas Adams |
Thomas Adams | |
Chief Executive Officer |
May 7, 2019 | /s/ Brigitte Lindsay |
Brigitte Lindsay | |
VP, Finance |
Document and Entity Information - shares |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Apr. 30, 2019 |
|
Document and Entity Information | ||
Entity Registrant Name | Trovagene, Inc. | |
Entity Central Index Key | 0001213037 | |
Document Type | 10-Q | |
Document Period End Date | Mar. 31, 2019 | |
Amendment Flag | false | |
Current Fiscal Year End Date | --12-31 | |
Entity Current Reporting Status | Yes | |
Entity Filer Category | Smaller Reporting Company | |
Entity Common Stock, Shares Outstanding | 5,245,217 | |
Document Fiscal Year Focus | 2019 | |
Document Fiscal Period Focus | Q1 |
CONDENSED BALANCE SHEETS (Parenthetical) - USD ($) |
Mar. 31, 2019 |
Dec. 31, 2018 |
---|---|---|
Preferred stock, par value (in USD per share) | $ 0.001 | $ 0.001 |
Preferred stock, shares authorized (in shares) | 20,000,000 | 20,000,000 |
Common stock, par value (in USD per share) | $ 0.0001 | $ 0.0001 |
Common stock, shares authorized (in shares) | 150,000,000 | 150,000,000 |
Common stock, shares issued (in shares) | 4,525,354 | 3,831,880 |
Common stock, shares outstanding (in shares) | 4,525,354 | 3,831,880 |
Series A Convertible Preferred Stock | ||
Preferred stock, shares authorized (in shares) | 277,100 | 277,100 |
Preferred stock, shares outstanding (in shares) | 60,600 | 60,600 |
Series A Convertible Preferred Stock, liquidation preference (in dollars) | $ 606,000 | $ 606,000 |
Series C Convertible Preferred Stock | ||
Preferred stock, shares outstanding (in shares) | 200,000 | 0 |
CONDENSED STATEMENT OF STOCKHOLDERS' EQUITY (Parenthetical) |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
| |
Statement of Stockholders' Equity [Abstract] | |
Cost of issuance of common stock, preferred stock and warrants | $ 40,000 |
Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment | $ 235,640 |
CONDENSED STATEMENTS OF CASH FLOWS (Parenthetical) |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
| |
Statement of Cash Flows [Abstract] | |
Discount of issuance of common stock, preferred stock and warrants for clinical trial funding commitment | $ 235,640 |
Organization and Basis of Presentation |
3 Months Ended | ||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||
Organization, Consolidation and Presentation of Financial Statements [Abstract] | |||||||||||||||||||||||||
Organization and Basis of Presentation | Organization and Basis of Presentation Business Organization and Overview Trovagene, Inc. (“Trovagene” or the “Company”) headquartered in San Diego, California, is a clinical-stage, oncology therapeutics company, taking a precision cancer medicine approach to develop drugs that target mitosis (cell division) to treat various types of cancer, including leukemias, lymphomas and solid tumors. Trovagene’s intellectual property and proprietary technology enables the Company to analyze circulating tumor DNA (“ctDNA”) and clinically actionable markers. Unique to the Company’s clinical development plan, and a key component of its precision cancer medicine approach, is the integration of predictive clinical biomarkers to identify patients most likely to respond to treatment. Basis of Presentation The accompanying unaudited interim condensed financial statements of Trovagene have been prepared in accordance with accounting principles generally accepted in the United States of America (“GAAP”) and the rules and regulations of the Securities and Exchange Commission (“SEC”) related to a quarterly report on Form 10-Q. Certain information and note disclosures normally included in annual financial statements prepared in accordance with GAAP have been condensed or omitted pursuant to those rules and regulations. The unaudited interim condensed financial statements reflect all adjustments consisting of normal recurring adjustments which, in the opinion of management, are necessary for a fair statement of the Company’s financial position and the results of its operations and cash flows for the periods presented. The unaudited condensed balance sheet at December 31, 2018 has been derived from the audited financial statements at that date but does not include all of the information and disclosures required by GAAP for annual financial statements. The operating results presented in these unaudited interim condensed financial statements are not necessarily indicative of the results that may be expected for any future periods. These unaudited interim condensed financial statements should be read in conjunction with the audited financial statements and the notes thereto for the year ended December 31, 2018 included in the Company’s annual report on Form 10-K filed with the SEC on March 6, 2019. The Company made a reverse split of its common stock, $0.0001 par value, at a ratio of 1 for 6, effective February 19, 2019. All share and per share information in the unaudited condensed financial statements and the accompanying notes have been retroactively adjusted to reflect the reverse stock split for all periods presented. Liquidity Trovagene’s condensed financial statements as of March 31, 2019 have been prepared under the assumption that Trovagene will continue as a going concern, which assumes that the Company will realize its assets and satisfy its liabilities in the normal course of business. The accompanying financial statements do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classifications of liabilities that may result from the outcome of the uncertainty concerning the Company’s ability to continue as a going concern. The Company has incurred net losses since its inception and has negative operating cash flows. Considering the Company’s current cash resources, including the net proceeds received from the offering of its equity securities in 2018 and 2019, management projects the Company’s existing resources will be sufficient to fund the Company’s planned operations into the fourth quarter of 2019. Based on its current business plan and assumptions, the Company expects to continue to incur significant losses and require significant additional capital to further advance its clinical trial programs and support its other operations. The Company has based its cash sufficiency estimates on its current business plan and its assumptions that may prove to be wrong. The Company could utilize its available capital resources sooner than it currently expects, and it could need additional funding to sustain its operations even sooner than currently anticipated. These circumstances raise substantial doubt about the Company’s ability to continue as a going concern. For the foreseeable future, the Company’s ability to continue its operations is dependent upon its ability to obtain additional capital. The Company cannot be certain that additional funding will be available on acceptable terms, or at all. To the extent that the Company can raise additional funds by issuing equity securities, the Company’s stockholders may experience significant dilution. If the Company is unable to raise additional capital when required or on acceptable terms, it may have to significantly delay, scale back or discontinue the development and/or commercialization of one or more of its product candidates, all of which would have a material adverse impact on the Company’s operations. The Company may also be required to:
The Company is evaluating the following options to raise additional capital, increase revenue, as well as reduce costs, in an effort to strengthen its liquidity position:
As of March 31, 2019, the Company has received approximately $3.3 million upon exercise of 497,313 warrants in connection with the June 2018 underwritten public offering. The Company continually assesses its spending plans to effectively and efficiently address its liquidity needs. |
Summary of Significant Accounting Policies |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Significant Accounting Policies | Summary of Significant Accounting Policies During the three months ended March 31, 2019, there have been no changes to the Company’s significant accounting policies as described in its Annual Report on Form 10-K for the fiscal year ended December 31, 2018, except as described below. Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities and non-current operating lease liabilities in the Company’s balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As its leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. See Note 5 for additional information of the Company’s leases. Net Loss Per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. The following table sets forth the computation of basic and diluted earnings per share:
The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:
Recently Adopted Accounting Pronouncement In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 changes accounting for leases and requires lessees to recognize the assets and liabilities arising from most leases, including those classified as operating leases under previous accounting guidance, on the balance sheet and requires disclosure of key information about leasing arrangements to increase transparency and comparability among organizations. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard. In July 2018, ASU 2018-11, Leases: Targeted Improvements, was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements. The Company adopted ASU 2016-02 in the first quarter of 2019 utilizing the modified retrospective transition method through a cumulative-effect adjustment at the beginning of the first quarter of 2019 and did not restate comparative periods. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date are or contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The Company did not elect to apply the hindsight practical expedient when determining lease term and assessing impairment of right-of-use assets. The adoption of ASU 2016-02 on January 1, 2019 resulted in the recognition of right-of-use assets of approximately $1,970,000 and lease liabilities for operating leases of approximately $2,503,000. There was no cumulative effect adjustment to accumulated deficit as a result of the adoption and there was not a material impact to the Company’s consolidated statement of operations. Refer to Note 5 to the condensed financial statements for further details. Recent Accounting Pronouncement Not Yet Adopted In August 2018, the FASB issued ASU No. 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements. |
Fair Value Measurements |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Measurements | Fair Value Measurements The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March 31, 2019 and December 31, 2018:
(1) Included as a component of cash and cash equivalents on the accompanying condensed balance sheets. The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2019:
The change in the fair value of the “derivative financial instruments—warrants” is recorded as a gain or loss in the Company’s statement of operations. A financial instrument’s level within the fair value hierarchy is based on the lowest level of any input that is significant to the fair value measurement. At each reporting period, the Company reviews the assets and liabilities that are subject to ASC Topic 815-40 and ASC Topic 480-10. At each reporting period, all assets and liabilities for which the fair value measurement is based on significant unobservable inputs or instruments that trade infrequently and therefore have little or no price transparency are classified as Level 3. |
Property and Equipment |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property and Equipment | Property and Equipment Property and equipment consist of the following:
|
Leases |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases | Leases As a lessee, the Company’s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. Master Facility Lease The Company leases a building in San Diego under an operating lease that expires on December 31, 2021. The lease currently requires fixed monthly rent payments of approximately $74,000, with 3% annual escalation. The lease also contains one five-year renewal option with minimum monthly rent equal to the then-current fair market value, subject to a 3% annual increase. As the Company is not reasonably certain to exercise this option, it has not been included in the calculation of the lease liability or right-of-use asset related to this lease. Facility Subleases As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, all of which expire October 31, 2019. Under the new standard, ROU assets and lease liabilities are not required to be established on the Company’s balance sheet for such operating subleases. The Company recorded a cease-use loss liability and expense in 2018 pursuant to ASC 420, Exit or Disposal Cost Obligations, representing the total expected shortfall in sublease income for two of the subleases as compared to its required payments for those spaces under the remainder of the master lease term. This liability was being amortized over the remaining lease term until the adoption of ASC 842, whereupon the remaining cease-use loss liability of approximately $487,000 was eliminated and treated as a reduction to the beginning ROU asset value for the master lease as of January 1, 2019. Income will continue to be recognized on a straight-line basis over the term of the sublease and will be reported on a gross basis as other revenue in the Company’s condensed statement of operations since the Company is not relieved of its primary obligation under the head lease. The components of lease expense were as follows:
Supplemental balance sheet information related to leases was as follows:
Supplemental cash flow and other information related to leases was as follows:
Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:
Total annual commitments under non-cancelable lease agreements for each of the years ended December 31 under the previous lease accounting guidance are as follows:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases | Leases As a lessee, the Company’s current leases include its master facility lease and immaterial equipment leases, all of which are considered operating leases. The Company (as a sublessor) also subleases portions of its facility to third parties under three separate subleases. All of these subleases have been determined to be operating leases and are accounted for separately from the head lease. Master Facility Lease The Company leases a building in San Diego under an operating lease that expires on December 31, 2021. The lease currently requires fixed monthly rent payments of approximately $74,000, with 3% annual escalation. The lease also contains one five-year renewal option with minimum monthly rent equal to the then-current fair market value, subject to a 3% annual increase. As the Company is not reasonably certain to exercise this option, it has not been included in the calculation of the lease liability or right-of-use asset related to this lease. Facility Subleases As a result of corporate restructurings in previous years, the Company vacated a portion of its facility and has subleased the space to third parties under three separate sublease agreements, all of which expire October 31, 2019. Under the new standard, ROU assets and lease liabilities are not required to be established on the Company’s balance sheet for such operating subleases. The Company recorded a cease-use loss liability and expense in 2018 pursuant to ASC 420, Exit or Disposal Cost Obligations, representing the total expected shortfall in sublease income for two of the subleases as compared to its required payments for those spaces under the remainder of the master lease term. This liability was being amortized over the remaining lease term until the adoption of ASC 842, whereupon the remaining cease-use loss liability of approximately $487,000 was eliminated and treated as a reduction to the beginning ROU asset value for the master lease as of January 1, 2019. Income will continue to be recognized on a straight-line basis over the term of the sublease and will be reported on a gross basis as other revenue in the Company’s condensed statement of operations since the Company is not relieved of its primary obligation under the head lease. The components of lease expense were as follows:
Supplemental balance sheet information related to leases was as follows:
Supplemental cash flow and other information related to leases was as follows:
Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:
Total annual commitments under non-cancelable lease agreements for each of the years ended December 31 under the previous lease accounting guidance are as follows:
|
Derivative Financial Instruments - Warrants |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Instruments and Hedging Activities Disclosure [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative Financial Instruments - Warrants | Derivative Financial Instruments — Warrants Based upon the Company’s analysis of the criteria contained in ASC Topic 815-40, Contracts in Entity’s Own Equity (“ASC 815-40”) or ASC Topic 480-10, Distinguishing Liabilities from Equity (“ASC 480-10”), Trovagene determined that certain warrants issued in connection with the execution of certain equity financings must be recorded as derivative liabilities. In accordance with ASC 815-40 and ASC 480-10, the warrants are also being re-measured at each balance sheet date based on estimated fair value, and any resultant change in fair value is being recorded in the Company’s condensed statements of operations. The Company estimates the fair value of these warrants using the Black-Scholes option pricing model. The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:
Expected volatility is based on historical volatility of Trovagene’s common stock. The warrants have a transferability provision and based on guidance provided in Staff Accounting Bulletin (“SAB”) No. 107, Share-Based Payment (“SAB No. 107”), for instruments issued with such a provision, Trovagene used the remaining contractual term as the expected term of the warrants. The risk-free rate is based on the U.S. Treasury security rates consistent with the expected remaining term of the warrants at each balance sheet date. The following table sets forth the components of changes in the Company’s derivative financial instruments—warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.
|
Stockholders' Equity |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity | Stockholders’ Equity Common Stock During the three months ended March 31, 2019, the Company issued a total of 693,475 shares of Common Stock. The Company issued 183,334 shares of its common stock, 150,000 warrants, and 200,000 shares of Series C Convertible Preferred Stock through a private placement in January 2019 to PoC Capital, LLC (“PoC”) in exchange for funding Company’s clinical trials in the aggregate amount of $1.675 million. 497,313 shares were issued upon exercise of warrants for a weighted-average price of $6.60. 6,362 shares were issued upon vesting of restricted stock units (“RSUs”). In addition, 6,466 shares were issued for share rounding as a result of the reverse stock split. Stock Options Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follow:
The unrecognized compensation cost related to non-vested stock options outstanding at March 31, 2019 and 2018, net of expected forfeitures, was $165,954 and $2,662,066, respectively, which is expected to be recognized over a weighted-average remaining vesting period of 0.8 and 1.8 years, respectively. The weighted-average remaining contractual term of outstanding options as of March 31, 2019 was approximately 7.2 years. The total fair value of stock options vested during the three months ended March 31, 2019 and 2018 was $188,984 and $971,488, respectively. The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:
A summary of stock option activity and changes in stock options outstanding is presented below:
On May 30, 2018, the number of authorized shares in the Trovagene 2014 Equity Incentive Plan (“2014 EIP”) was increased from 791,667 to 1,458,334. As of March 31, 2019 there were 114,429 shares available for issuance under the 2014 EIP. Restricted Stock Units The weighted-average grant date fair value of the RSUs was $4.04 per share during the three months ended March 31, 2019. There were no RSU granted during the three months ended March 31, 2018. A summary of the RSU activity is presented below:
At March 31, 2019, total unrecognized compensation cost related to non-vested RSUs was $149,586, which is expected to be recognized over a weighted-average period of 1.5 years. The total fair value of vested RSUs during the three months ended March 31, 2019 and 2018 were $126,983 and $1,070,914, respectively. Warrants A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
Series C Convertible Preferred Stock On January 25, 2019, the Company entered into a Master Services Agreement and a Stock and Warrant Subscription Agreement with PoC, whereby PoC has agreed to finance $1.675 million in clinical studies, including the development costs associated with Phase 1b/2 trial of onvansertib in combination with FOLFIRI and Avastin® in patients with metastatic Colorectal Cancer (“mCRC”) harboring KRAS mutation in exchange for (i)183,334 shares of common stock, (ii) warrants to purchase an aggregate of 150,000 shares of common stock, with an exercise price of $3.762 per share, expiring on January 25, 2024, and (iii) 200,000 shares of Series C Convertible Preferred Stock, each share of which is convertible into 1.67 shares of common stock. The Company evaluated the awards issued under this transaction and determined they should be classified as equity. These equity awards were fully vested and nonforfeitable. Since the equity awards were for clinical study services yet to be provided, the Company recognized $1.675 million service receivables as contra equity. The Company releases the service receivables as clinical study services are performed. The conversion feature of the Series C Convertible Preferred Stock at the time of issuance was determined to be beneficial on commitment date. Because the Series C Convertible Preferred Stock is perpetual with no stated maturity date, and the conversions may occur any time from inception, the Company immediately recorded a non-cash deemed dividend of $0.3 million related to the beneficial conversion feature arising from the issuance of Series C Convertible Preferred Stock. This non-cash deemed dividend increased the Company’s net loss attributable to common stockholders and net loss per share. The holders of Series C Convertible Preferred Stock shall have the right to vote on an as-converted to Common Stock (limited to 93.41% of the then as if converted Common Stock) all matters submitted to a vote of holders of the Company’s Common Stock. In the event of liquidation, dissolution or winding-up, holders of Series C Convertible Preferred Stock will be entitled to receive the same amount that a holder of the Company’s Common Stock would receive if the Series C Convertible Preferred Stock were fully converted into shares of the Company’s Common Stock at the conversion price which amounts shall be paid pari passu with all holders of Common Stock. As of March 31, 2019, there were 200,000 shares of Series C Convertible Preferred Stock outstanding. |
Commitments and Contingencies |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Commitments and Contingencies Disclosure [Abstract] | |
Commitments and Contingencies | Commitments and Contingencies Executive and Consulting Agreements The Company has longer-term contractual commitments with various consultants and employees. Certain employment agreements provide for severance payments. Research and Development and Clinical Trial Agreements In March 2017, the Company entered into a license agreement with Nerviano Medical Sciences S.r.l. (“Nerviano”) which granted the Company development and commercialization rights to NMS-1286937, which Trovagene refers to as onvansertib. Onvansertib is an oral, investigative drug and a highly-selective adenosine triphosphate competitive inhibitor of the serine/threonine PLK 1. The Company plans to develop onvansertib in patients with leukemias/lymphomas and solid tumor cancers. Upon execution of the agreement, the Company paid $2.0 million in license fees which were expensed to research and development costs. Under the agreement, the Company is committed to purchase $1.0 million for services provided by Nerviano, such as service for manufacturing drug product, no later than June 30, 2019. As of March 31, 2019, services of approximately $950,000 have been ordered. Terms of the agreement also provide for the Company to pay royalties based on certain development and sales milestones. The Company is a party to various agreements under which it licenses technology on an exclusive basis in the field of human diagnostics and oncology therapeutics. License fees are generally calculated as a percentage of product revenues, with rates that vary by agreement. To date, payments have not been material. Litigation Trovagene does not believe that it has legal liabilities that are probable or reasonably possible that require either accrual or disclosure. From time to time, the Company may become involved in various lawsuits and legal proceedings that arise in the ordinary course of business. Litigation is subject to inherent uncertainties, and an adverse result in matters may arise from time to time that may harm the Company’s business. As of the date of this report, management believes that there are no claims against the Company, which it believes will result in a material adverse effect on the Company’s business or financial condition. |
Related Party Transactions |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Related Party Transactions [Abstract] | |
Related Party Transactions | Related Party Transactions In November 2018, the Company entered into a Material Transfer Agreement (“MTA”) with Leucadia Life Sciences (“Leucadia”) pursuant to which Leucadia will develop a PCR-based assay for onvansertib for AML. The cost of the services under the MTA are expected to be up to $575,796. The Company’s CEO, Dr. Thomas Adams, is a principal stockholder of Leucadia. In addition, in connection with the MTA, the Company entered into a consulting agreement with Tommy Adams, VP of Operations of Leucadia, who is the son of Dr. Adams. During the three months ended March 31, 2019, the Company incurred and recorded approximately $254,000 of research and development expenses for services performed by Leucadia and Tommy Adams. |
Subsequent Event |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Subsequent Events [Abstract] | |
Subsequent Event | Subsequent Event On April 4, 2019, the Company entered into a securities purchase agreement with Lincoln Park Capital Fund, LLC (“LPC”), pursuant to which it sold to LPC, in a registered direct offering, an aggregate of (i) 225,813 shares of common stock, and (ii) 156,353 Series A warrants to purchase shares of its common stock, at a price of $3.925 per share or Series A warrant. The Series A warrants are pre-funded warrants which are exercisable immediately with an exercise price of $0.01 per share, expiring 5 years following the date of issuance. In a concurrent private placement, the Company also sold to LPC 382,166 Series B warrants to purchase shares of its common stock, with an exercise price of $3.80 per share, expiring 5.5 years following the date of issuance. The Series B Warrants are exercisable six month following the date of issuance. Total gross proceeds to the Company, before deducting any offering expenses, was $1.5 million. |
Summary of Significant Accounting Policies (Policies) |
3 Months Ended |
---|---|
Mar. 31, 2019 | |
Accounting Policies [Abstract] | |
Leases | Leases The Company determines if an arrangement is a lease at inception. Operating leases are included in operating lease right-of-use (“ROU”) assets, current operating lease liabilities and non-current operating lease liabilities in the Company’s balance sheets. ROU assets represent the Company’s right to use an underlying asset for the lease term and lease liabilities represent its obligation to make lease payments arising from the lease. Operating lease ROU assets and liabilities are recognized at commencement date based on the present value of lease payments over the lease term. As its leases do not provide an implicit rate, the Company uses its incremental borrowing rate based on the information available at commencement date in determining the present value of lease payments. The operating lease ROU asset also includes any lease payments made less lease incentives received. The Company’s lease terms may include options to extend or terminate the lease when it is reasonably certain that the Company will exercise that option. Lease expense is recognized on a straight-line basis over the lease term. |
Net Loss Per Share | Net Loss Per Share Basic and diluted net loss per share is presented in conformity with ASC Topic 260, Earnings per Share, for all periods presented. In accordance with this guidance, basic net loss per common share was determined by dividing net loss applicable to common stockholders by the weighted-average common shares outstanding during the period. Preferred dividends are included in income available to common stockholders in the computation of basic and diluted earnings per share. Diluted net loss per share is computed by dividing the net loss by the weighted average number of common shares and common share equivalents outstanding for the period. Common share equivalents are only included when their effect is dilutive. |
Recently Adopted Accounting Pronouncement | Recently Adopted Accounting Pronouncement In February 2016, the FASB issued ASU 2016-02, Leases (Topic 842) (“ASU 2016-02”). ASU 2016-02 changes accounting for leases and requires lessees to recognize the assets and liabilities arising from most leases, including those classified as operating leases under previous accounting guidance, on the balance sheet and requires disclosure of key information about leasing arrangements to increase transparency and comparability among organizations. In July 2018, the FASB issued ASU 2018-10, Codification Improvements to Topic 842, which provides narrow amendments to clarify how to apply certain aspects of the new lease standard. In July 2018, ASU 2018-11, Leases: Targeted Improvements, was issued to provide relief to companies from restating comparative periods. Pursuant to this ASU, in the period of adoption the Company will not restate comparative periods presented in its financial statements. The Company adopted ASU 2016-02 in the first quarter of 2019 utilizing the modified retrospective transition method through a cumulative-effect adjustment at the beginning of the first quarter of 2019 and did not restate comparative periods. The Company has elected the package of practical expedients, which allows the Company not to reassess (1) whether any expired or existing contracts as of the adoption date are or contain a lease, (2) lease classification for any expired or existing leases as of the adoption date and (3) initial direct costs for any existing leases as of the adoption date. The Company did not elect to apply the hindsight practical expedient when determining lease term and assessing impairment of right-of-use assets. The adoption of ASU 2016-02 on January 1, 2019 resulted in the recognition of right-of-use assets of approximately $1,970,000 and lease liabilities for operating leases of approximately $2,503,000. There was no cumulative effect adjustment to accumulated deficit as a result of the adoption and there was not a material impact to the Company’s consolidated statement of operations. Refer to Note 5 to the condensed financial statements for further details. Recent Accounting Pronouncement Not Yet Adopted In August 2018, the FASB issued ASU No. 2018-13, Changes to the Disclosure Requirements for Fair Value Measurement. This ASU eliminates, adds and modifies certain disclosure requirements for fair value measurements as part of its disclosure framework project. The standard is effective for all entities for financial statements issued for fiscal years beginning after December 15, 2019, and interim periods within those fiscal years. Early adoption is permitted. The adoption of this guidance is not expected to have a material impact on the Company’s financial statements. |
Summary of Significant Accounting Policies (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Accounting Policies [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Computation of Basic and Diluted Earnings per Share | The following table sets forth the computation of basic and diluted earnings per share:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Antidilutive Securities Excluded from the Calculation of Diluted Net Loss per Share | The following table sets forth the outstanding potentially dilutive securities that have been excluded in the calculation of diluted net loss per share because their effect was anti-dilutive:
|
Fair Value Measurements (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Fair Value Disclosures [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of the Company’s Assets and Liabilities that are Measured and Recognized at Fair Value on a Recurring Basis Classified Under the Appropriate Level of the Fair Value Hierarchy | The following table presents the Company’s assets and liabilities that are measured and recognized at fair value on a recurring basis classified under the appropriate level of the fair value hierarchy as of March 31, 2019 and December 31, 2018:
(1) Included as a component of cash and cash equivalents on the accompanying condensed balance sheets. |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Changes in the Fair Value of the Company’s Level 3 Liabilities | The following table sets forth a summary of changes in the fair value of the Company’s Level 3 liabilities for the three months ended March 31, 2019:
|
Property and Equipment (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Property, Plant and Equipment [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Components of Property and Equipment | Property and equipment consist of the following:
|
Leases (Tables) |
3 Months Ended | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Leases [Abstract] | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Lease Expense and Supplemental Cash Flow Information | Supplemental cash flow and other information related to leases was as follows:
The components of lease expense were as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Supplemental Balance Sheet Information | Supplemental balance sheet information related to leases was as follows:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Future Minimum Lease Payments | Total remaining annual commitments under non-cancelable lease agreements for each of the years ended December 31 are as follows:
Total annual commitments under non-cancelable lease agreements for each of the years ended December 31 under the previous lease accounting guidance are as follows:
|
Derivative Financial Instruments - Warrants (Tables) - Black Scholes Option Pricing Method |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Derivative financial instruments | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Assumptions Used to Determine the Fair Value of the Warrants | The range of assumptions used to determine the fair value of the warrants valued using the Black-Scholes option pricing model during the periods indicated was:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Components of Changes in the Company’s Derivative Financial Instruments Liability Balance | The following table sets forth the components of changes in the Company’s derivative financial instruments—warrants liability balance, valued using the Black-Scholes option pricing method, for the periods indicated.
|
Stockholders' Equity (Tables) |
3 Months Ended | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Mar. 31, 2019 | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Stockholders' Equity Note [Abstract] | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Stock-Based Compensation Expense | Stock-based compensation expense related to Trovagene equity awards have been recognized in operating results as follow:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Assumptions to Estimate Fair Value of Stock Option Awards | The estimated fair value of stock option awards was determined on the date of grant using the Black-Scholes option valuation model with the following weighted-average assumptions during the following periods indicated:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Stock Option Activity and of Changes in Stock Options Outstanding | A summary of stock option activity and changes in stock options outstanding is presented below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Schedule of Share-based Compensation, Restricted Stock and Restricted Stock Units Activity | A summary of the RSU activity is presented below:
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Summary of Warrant Activity and Changes in Warrants Outstanding | A summary of warrant activity and changes in warrants outstanding, including both liability and equity classifications is presented below:
|
Organization and Basis of Presentation (Details) |
3 Months Ended | |||
---|---|---|---|---|
Feb. 19, 2019 |
Mar. 31, 2019
USD ($)
$ / shares
shares
|
Mar. 31, 2018
USD ($)
|
Dec. 31, 2018
$ / shares
|
|
Subsequent Event [Line Items] | ||||
Common stock, par value (in USD per share) | $ / shares | $ 0.0001 | $ 0.0001 | ||
Proceeds from exercise of warrants | $ | $ 3,282,266 | $ 1,449,167 | ||
Warrant exercised (in shares) | 497,313 | |||
Common Stock | ||||
Subsequent Event [Line Items] | ||||
Stock split, ratio | 0.1667 | |||
Warrant exercised (in shares) | 497,313 |
Summary of Significant Accounting Policies - Net Loss Per Share (Details) - USD ($) |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Numerator: | ||
Numerator: Net loss attributable to common shareholders | $ (4,179,100) | $ (4,792,237) |
Net loss used for diluted loss per share | $ (4,179,100) | $ (4,792,237) |
Denominator for basic and diluted net loss per share: | ||
Weighted-average shares used to compute basic loss per share (in shares) | 4,086,561 | 768,951 |
Weighted-average shares used to compute diluted net loss per share (in shares) | 4,086,561 | 768,951 |
Net loss per share attributable to common stockholders: | ||
Net loss per common share - basic (in USD per share) | $ (1.02) | $ (6.23) |
Net loss per common share - diluted (in USD per share) | $ (1.02) | $ (6.23) |
Summary of Significant Accounting Policies - Narrative (Details) - USD ($) |
Mar. 31, 2019 |
Jan. 01, 2019 |
Dec. 31, 2018 |
---|---|---|---|
Accounting Policies [Abstract] | |||
Operating lease right-of-use assets | $ 1,816,286 | $ 1,970,000 | $ 0 |
Total | $ 2,316,459 | $ 2,503,000 |
Fair Value Measurements - Changes in Fair Value of Level 3 Liabilities (Details) - Warrants |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
| |
Reconciliation of the beginning and ending balances | |
Balance at December 31, 2018 | $ 32,315 |
Realized (gains) or losses | 9,761 |
Balance at March 31, 2019 | $ 42,076 |
Property and Equipment (Details) - USD ($) |
Mar. 31, 2019 |
Dec. 31, 2018 |
---|---|---|
Property, equipment and depreciation and amortization | ||
Property and equipment, gross | $ 1,559,768 | $ 3,414,494 |
Less—accumulated depreciation and amortization | (1,266,407) | (2,110,061) |
Property and equipment, net | 293,361 | 1,304,433 |
Furniture and office equipment | ||
Property, equipment and depreciation and amortization | ||
Property and equipment, gross | 775,030 | 775,030 |
Leasehold improvements | ||
Property, equipment and depreciation and amortization | ||
Property and equipment, gross | 102,230 | 1,962,230 |
Laboratory equipment | ||
Property, equipment and depreciation and amortization | ||
Property and equipment, gross | $ 682,508 | $ 677,234 |
Leases - Narrative (Details) |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2019
USD ($)
renewal_option
lease
|
Jan. 01, 2019
USD ($)
|
Dec. 31, 2018
USD ($)
|
|
Lessee, Lease, Description [Line Items] | |||
Monthly rent payments | $ 74,000 | ||
Annual rent increase, percentage | 3.00% | ||
Number of lease renewals | renewal_option | 1 | ||
Renewal term | 5 years | ||
Number of subleases | lease | 3 | ||
Decrease in operating lease right-of-use assets | $ (1,816,286) | $ (1,970,000) | $ 0 |
Accounting Standards Update 2016-02 | |||
Lessee, Lease, Description [Line Items] | |||
Decrease in operating lease right-of-use assets | $ (487,000) |
Leases - Components of Lease Expense (Details) |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
| |
Leases [Abstract] | |
Operating lease cost | $ 194,462 |
Operating sublease income | (99,937) |
Net operating lease cost | $ 94,525 |
Leases - Supplemental Balance Sheet Information (Details) - USD ($) |
3 Months Ended | ||
---|---|---|---|
Mar. 31, 2019 |
Jan. 01, 2019 |
Dec. 31, 2018 |
|
Leases [Abstract] | |||
Operating lease ROU assets | $ 1,816,286 | $ 1,970,000 | $ 0 |
Current operating lease liabilities | 796,246 | 0 | |
Non-current operating lease liabilities | 1,520,213 | $ 0 | |
Total operating lease liabilities | $ 2,316,459 | $ 2,503,000 | |
Weighted-average remaining lease term–operating leases | 2 years 9 months 4 days | ||
Weighted-average discount rate–operating leases | 6.50% |
Leases - Supplemental Cash Flow Information (Details) |
3 Months Ended |
---|---|
Mar. 31, 2019
USD ($)
| |
Leases [Abstract] | |
Operating cash flows from operating leases | $ 226,364 |
Operating leases | $ 2,503,148 |
Leases - Future Minimum Lease Payments (Details) - USD ($) |
Mar. 31, 2019 |
Jan. 01, 2019 |
Dec. 31, 2018 |
---|---|---|---|
Operating Leases | |||
2019 (excluding the three months ended March 31, 2019) | $ 614,107 | ||
2020 | 941,670 | ||
2021 | 968,165 | ||
2022 | 5,868 | ||
2023 | 3,423 | ||
Total future minimum lease payments | 2,533,233 | ||
Less imputed interest | (216,774) | ||
Total | 2,316,459 | $ 2,503,000 | |
Sublease Income | |||
2019 (excluding the three months ended March 31, 2019) | 233,187 | ||
2020 | 0 | ||
2021 | 0 | ||
2022 | 0 | ||
2023 | 0 | ||
Total future minimum lease payments | 233,187 | ||
Net Operating Leases | |||
2019 (excluding the three months ended March 31, 2019) | 380,920 | ||
2020 | 941,670 | ||
2021 | 968,165 | ||
2022 | 5,868 | ||
2023 | 3,423 | ||
Total future minimum lease payments | $ 2,300,046 | ||
Operating Leases | |||
2019 | $ 914,540 | ||
2020 | 941,670 | ||
2021 | 968,165 | ||
2022 | 5,868 | ||
2023 | 3,423 | ||
Total | 2,833,666 | ||
Sublease Income | |||
2019 | (333,124) | ||
2020 | 0 | ||
2021 | 0 | ||
2022 | 0 | ||
2023 | 0 | ||
Total | 333,124 | ||
Net Operating Leases | |||
2019 | 581,416 | ||
2020 | 941,670 | ||
2021 | 968,165 | ||
2022 | 5,868 | ||
2023 | 3,423 | ||
Total | $ 2,500,542 |
Stockholders' Equity - Stock-based Compensation Expense (Details) - USD ($) |
3 Months Ended | |
---|---|---|
Mar. 31, 2019 |
Mar. 31, 2018 |
|
Stock-based compensation expense | ||
Total stock based compensation expense | $ 200,067 | $ 1,406,131 |
Options vested, fair value | 188,984 | 971,488 |
Research and Development Expense | ||
Stock-based compensation expense | ||
Total stock based compensation expense | 110,081 | 395,709 |
Cost of Revenue | ||
Stock-based compensation expense | ||
Total stock based compensation expense | 0 | 39,631 |
Selling, general and administrative expense | ||
Stock-based compensation expense | ||
Total stock based compensation expense | 89,986 | 970,791 |
Stock Option | ||
Stock-based compensation expense | ||
Unrecognized compensation cost | $ 165,954 | $ 2,662,066 |
Weighted-average remaining vesting period for recognition | 9 months 29 days | 1 year 9 months 15 days |
Options outstanding, weighted average contractual life | 7 years 2 months 9 days |
Stockholders' Equity - Warrants (Details) - $ / shares |
3 Months Ended | 12 Months Ended |
---|---|---|
Mar. 31, 2019 |
Dec. 31, 2018 |
|
Number of Warrants | ||
Balance of warrants outstanding at the beginning of the period (in shares) | 3,649,341 | |
Granted (in shares) | 150,065 | |
Exercised (in shares) | (497,313) | |
Balance of warrants outstanding at the end of the period (in shares) | 3,302,093 | 3,649,341 |
Weighted Average Exercise Price Per Share | ||
Weighted average exercise price of warrants at the beginning of the period (in USD per share) | $ 8.91 | |
Granted (in USD per share) | 3.76 | |
Exercised (in USD per share) | 6.60 | |
Weighted average exercise price of warrants at the end of the period (in USD per share) | $ 9.02 | $ 8.91 |
Term | ||
Weighted-Average Remaining Contractual Term | 4 years 2 months 12 days | 4 years 4 months 21 days |
Commitments and Contingencies (Details) - Nerviano - USD ($) $ in Thousands |
1 Months Ended | ||
---|---|---|---|
Mar. 31, 2017 |
Mar. 31, 2019 |
Mar. 13, 2017 |
|
Other Commitments [Line Items] | |||
Other commitment | $ 1,000 | ||
Research and Development Arrangement | |||
Other Commitments [Line Items] | |||
Other commitment | $ 950 | ||
Licensing Agreements | |||
Other Commitments [Line Items] | |||
Research and development expense | $ 2,000 |
Related Party Transactions (Details) - USD ($) $ in Thousands |
1 Months Ended | 3 Months Ended |
---|---|---|
Nov. 30, 2018 |
Mar. 31, 2019 |
|
Related Party Transaction [Line Items] | ||
Related party committed expenditures | $ 576 | |
Affiliated Entity | ||
Related Party Transaction [Line Items] | ||
Research and development expense | $ 254 |
QD+1>5?F6-%9O2 S#C[CH4KWARHGTT9@G$4\9\7;WWT4FQV^XQ< M&$
M.8X8NL3,".+9YQ)TK<21?DZG_R'8KFK<1H+M.XVWZP3I*D$:"=)W"M(/38Z8
M?<2HB*';W3Y-/M0AB\%*,$U<*8M*W:NXSHOHO+5W-%[,&WQ<^9_,-%Q9=-;.
M7V^\A%IK!UY- $NPG=_*$S7"=)5@C02I/\M<2WF^J\D;-%3!;:)
MT^1(:7H=)WGAG0?V+HEO\CM\G/9OW#9".W(V'E\V]K\VQ@-*V5SA"+7XP69#
M0NW#\1;/=ARST?"FFWX0F[]Q\0%02P,$% @ [("G3FYD.KBU 0 T@,
M !D !X;"]W;W)K ,"S&\=L-(+MIA_$YF]<_ )02P,$% @ [("G3J)T/L>U 0 T@, !D
M !X;"]W;W)K
M"G1/C)E[N^B\<^],MLJL7E 9DO^*;YA(N%(B8U24:G0 G IP),/R0$$R$8";X'Q/"B1 :!#"FHFNS1P(5.:.#P\:WVR-UB?Q-
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M?$/LTG3<.5(AVYMN0F=*!992O"=Y#6HYQ^8-P6>AEHE \Z@LV-,& :/#[.\#S7;&< ATG!!P::<6)L$'QD3$K!9P:R#PW"Z%BJ!07]
MG;<(.)Y0@JV.;*]'$\<;@CV*^">6&[8I"H!RR?BI$UB=Y1&AP52VL*&1[6BK
MLSL#BOI2"SZA SL:V9:FA, 4&+8B]N ZP(_[2;G
MR\:;D*0%D4Z2LG]Y@5>(.<2QH*J!LK^%WBY7RDOG6":>VF;A%DB=5H4K*Q[6
M-;:F8FO=R(-5'?(6E=;!2+1=HW)KI0MC8R]ANWJCV4"VS>&(!-3:U6D3PA5I
M2?95]S)KMA$I6?6:&+WD.VT=PO!I'(OJVZM0E\]\1 <[,03 [V/!@_@P2Q[T
M(TQC%0]F@\ZP]Z-$9\RH1]J(EI[^W/SV-:5K ]YL<<%Y<2]Z0)$DYOF7YGY<
MYU;VL%^RO8=.0%TG]J4S/^*\A=02P,$% @ [("G3DLAW-RU 0
MT@, !D !X;"]W;W)K
]"$^\
M.W'?FS(X8ROBG4_>>N^MX$F:L5L0FC'G"<-7F-V"8%Y]"<&W0ISY?W2^3=]O
M9KB/]/TZ^N&X+9!N"J11(/VGQ/LW)6YA#F^"L%5/-9@F3I,E)0Y=G.25=QG8
M!Q[?Y"]\FO:OPC2RL^2*SK]L['^-Z,"GDMSY$6K]!UL,!;4+QW?^;*8QFPR'
M_?R#V/*-BS]02P,$% @ [("G3@ F-FK4 0 G 0 !D !X;"]W;W)K
M
S?BHO=?VCO_ASNPRB?D2F-)NN#Y';P[MY,F791[+C^'<,&EPT
M>\?K\]_1/P^3MY-YR5OS5)??BVVW7P9I,-N:7?Y6=E_KTQ]FG%
M36G-^Y%8C4U=ML/O;//6=G4U1K%#J?*?YV-Q&(ZG\S]Q-KIA!QH=Z.*@]%T'
M'AUXJH,>';3C$)ZG,JS-.N_RU:*I3[/F_'B/>9]%ZD';U=_T-X?%'OZSR]/:
MN^\KCN:+\+T/--H\GFWHRH9N+9Z 1>Q$60.;_TU".\C+2 F.E 9_OAEIB@,P
M#,!# 'T3('.F>K9)!IO#8),HK2+/0#74T5)'18[.V2:^TLFT2N81UHFA3@QT
ME*,32YTD54F,=1*HDP =)P$>$Z$3IXGGZ>9:;&3YN]B9XS+,PF G
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M+ 9-_H )((;-4, NQA^P,89]C&\Q<@<:YIOE>4;'99G"MZ-MZ/I)*?; D=J[:K
M:2=&-EW'%O5MX^H?4$L#!!0 ( .R ITX^R4W(=0, *T. 9 >&PO
M=V]R:W-H965TM\-L7Y;TO/Z"H(G[Q**HEWA,C=[[Y3?Z??>^\\1$-@,.*QR%P0#U][JS!8_+4(,D1"
M@O5MD'AG4?B0PNZ#. (43:+ !V0 U5;"_3C?PA0^:-_S-$X?=CA!%FS" F"7
MD]B'*7S _B^$C1[I#Z26SU'?RCQ0YT%C![83;("M!/,5LD'A;O466?$ ZLH*
M=%B@P0=@(X!5*1[3T3R,8[(#<+#7Q#M!LFQ!,P!2+N"CW895?I['1Q=D7"Q8
MW!1?PG44@ $>[]:;5;H.1+@' >QM"U!J\HY7.K[>Y%U.! I2>KXM,(QE)@;@
M+V!9$*/8AO-5PH<1)A2_HE,7QXTK#9(@WOT-.'V4S
+;I6W;CC=]YMV'X!;80 ^:D,$*:L4UG+Y:P)_% ,X^CD*S+AY!)
MF5CA$P+F21H&F 6?J;@.KAD!(% 8CB1&'K<,'E-^B8998P3)&,Q$Z7
K!+DIK]8D;B/TAX0H;(@OC*%Q*[@M'%(I,
M9LR%E8X?.D[B72KWX;J4_ -R%]:B4FWX+0J%ROMDEH:,A@S/$;IF*&N8R"OJ
M$T?DN(&D88.6Q(J640:X7HFOB?".U'76!&BZ!K#-4EE-@]&+TWO6(=#&0GGM
M F^N;M(="YYK7*@3=L&]F2A=OQ:6Q8M]YV+'R<*8LU3HX(/Y%Q2LE &(R0AS
MD5V_H!0_%:>/*?G(A E.2TR$75D@^EZC?L7Q/8XDRM" "H6B!PQGD
U-M2M@MH\PZG2C9<-G>T^1-?EBZ5''[3W/ V
M<6]%X2"%